Uterine Fibroid Embolization — Cost, Top Hospitals & Success Rates | MyMedicPlus

Uterine fibroid embolization (UFE), also called uterine artery embolization (UAE), is a minimally invasive interventional radiology procedure that treats symptomatic uterine fibroids (leiomyomata) without surgery. Under fluoroscopic guidance, an interventional radiologist inserts a catheter through a small groin or wrist puncture, navigates to the uterine arteries, and injects small embolic particles (typically polyvinyl alcohol — PVA — particles, 500-700 µm, or Embospheres) into both uterine arteries. This cuts off the blood supply to the fibroids — which have a more robust arterial supply than normal myometrium — causing fibroid ischemia, infarction, and progressive shrinkage over the following months, while the normal uterine tissue survives via collateral supply. MRI is performed before UAE to characterize fibroid type, location, size (Funaki classification), and uterine anatomy; and after to assess fibroid devascularization and volume reduction. The procedure was first described in France in 1995 by Jacques Ravina and has since been performed in over 500,000 patients worldwide with a safety record comparable to hysterectomy. UAE is approved by NICE (National Institute for Health and Care Excellence, UK), the American College of Radiology, and the Society of Interventional Radiology as an established treatment for symptomatic uterine fibroids.

UFE is indicated for symptomatic uterine fibroids (leiomyomata) causing: heavy menstrual bleeding (menorrhagia) — the most common indication, affecting quality of life and causing iron-deficiency anemia; fibroid-related pelvic bulk symptoms — pelvic pressure, urinary frequency/urgency (fibroid compression of bladder), constipation (posterior fibroid compression of rectum), feeling of pelvic fullness or heaviness; pain — dysmenorrhea (painful periods), dyspareunia (painful intercourse), chronic pelvic pain; reproductive complications — recurrent pregnancy loss associated with submucosal fibroids distorting the endometrial cavity; and large uterine size causing cosmetic concern or abdominal distension. Fibroid types treated: intramural fibroids (within the uterine wall — 70% of fibroids; respond well to UAE); submucosal fibroids (beneath the endometrial lining — cause the most severe menorrhagia; small purely submucosal fibroids may be better treated hysteroscopically); subserosal fibroids (on the uterine surface — respond to UAE for bulk symptoms; pedunculated subserosal fibroids are contraindicated due to necrosis and detachment risk). Contraindications: pedunculated subserosal fibroids with stalk <2cm (risk of necrosis and peritonitis from detachment), active pelvic infection, suspected or confirmed malignancy (leiomyosarcoma), pregnancy, severe contrast allergy, and desire for future fertility (relative contraindication — fertility possible post-UAE but success rates lower than myomectomy).

Patient evaluation for UFE: MRI pelvis with contrast (essential pre-procedure) — confirms fibroid vs adenomyosis (UAE is less effective for pure adenomyosis); fibroid number, location, size, vascularity on T2-weighted and gadolinium-enhanced sequences (Funaki Type I — high vascularity on gadolinium, best response; Type III — low vascularity, poor response); measures uterine artery anatomy and dominant ovarian supply variants; excludes leiomyosarcoma features. Gynecological evaluation: pap smear (current), pelvic ultrasound; premenopausal women with confirmed fibroid diagnosis; heavy menstrual bleeding confirmed by PBAC score or pictogram; exclude endometrial pathology (endometrial biopsy if heavy bleeding with risk factors for endometrial cancer — age >40, obesity, PCOS, tamoxifen use). Coagulation: INR <1.5, platelets >50,000; antiplatelet agents — stop 5-7 days before; DOACs — hold 24-48 hours. Renal function: eGFR >30 for contrast; hydration protocol if eGFR 30-60. Fertility counseling: patients wishing to conceive are counseled that UAE is associated with lower pregnancy rates and higher miscarriage rates than myomectomy (based on FUME trial data); myomectomy remains preferred for fertility preservation. Post-menopausal women are poor candidates (fibroids typically regress naturally; malignancy must be excluded). Ideal candidates: premenopausal women with symptomatic fibroids on imaging, failed medical therapy (combined oral contraceptives, progestogens, levonorgestrel IUS, tranexamic acid, GnRH analogues), who desire uterine preservation and have completed or defer childbearing.

Uterine Fibroid Embolization employs image-guided minimally invasive techniques performed in a dedicated catheterization laboratory or interventional radiology suite under fluoroscopy, ultrasound, CT, or biplane DSA guidance. Patient preparation: fasting 4–6 hours, IV access, baseline coagulation profile (INR <1.5, platelets >50,000 for most procedures), renal function (pre-hydration if eGFR <45 and contrast anticipated), pre-procedure antiplatelet loading (aspirin 300 mg + clopidogrel 300 mg loading for coronary procedures). Access: femoral artery (4–6 French sheath, right groin — standard for most procedures) or radial artery (5–6 French — preferred for coronary procedures; immediate ambulation; lower bleeding complications). Seldinger technique: percutaneous puncture → guidewire → introducer sheath → diagnostic catheter → exchange for working catheter and devices. Contrast-enhanced roadmap angiography defines the target anatomy before intervention. Device selection depends on lesion characteristics: drug-eluting stents (DES) for coronary restenosis prevention; self-expanding metallic stents (NITINOL) for venous and biliary applications; balloon-expandable stents for precise deployment at ostial lesions; drug-coated balloons (DCB) for below-the-knee and in-stent restenosis. Haemostasis post-procedure: manual pressure 10–15 minutes for femoral access; radial compression band for 3–4 hours; closure device (Angioseal, Perclose) for larger sheaths. Antiplatelet therapy (aspirin + P2Y12 inhibitor) prescribed for 1–12 months post-stent based on indication. Patient and family education about treatment goals, expected timeline, and self-management strategies is integrated throughout treatment delivery, supporting adherence and optimising long-term outcomes.

UAE achieves excellent control of fibroid-related symptoms. Menorrhagia reduction: 85-90% reduction in menstrual blood loss (measured by PBAC score); 90-95% of patients report improvement in heavy bleeding; complete resolution of menorrhagia in 60-70% of patients. Bulk symptoms: urinary frequency/pressure symptoms improve in 70-80%; pelvic pain and bulk symptoms resolve in 75-85%. Fibroid volume reduction: mean reduction 40-65% at 6 months; 50-80% at 24 months for dominant fibroid; uterine volume reduction 25-40%. Patient satisfaction: 80-85% satisfaction at 2-year follow-up. EMMY trial (multinational randomized controlled trial, UAE vs hysterectomy for heavy menstrual bleeding): UAE achieved equivalent clinical improvement at 1 year to hysterectomy in 80% of patients, with shorter hospitalization and faster return to work; at 5-year follow-up, 23% of UAE patients had required hysterectomy for ongoing symptoms. Uterus preserved in 85-90% of UAE patients long-term (hysterectomy avoided). Hospital stay typically 1-2 days vs 4-7 days for hysterectomy. Return to work: 1-2 weeks for UAE vs 4-8 weeks for abdominal hysterectomy. Quality of life: UFS-QOL scores improve significantly — comparable improvement to hysterectomy at 12-24 months. FEMME trial (UAE vs myomectomy) showed equivalent QoL improvement at 2 years for both procedures.

Post-embolization syndrome (PES): the most expected adverse event — occurs in 90% of UAE patients to some degree; crampy pelvic pain, fever (38-39°C), nausea, fatigue developing 24-48 hours post-procedure as fibroids undergo ischemic infarction; typically resolves within 5-7 days; managed with adequate analgesia (patient-controlled analgesia — morphine + ketorolac — in hospital for first 12-24 hours, NSAIDs + paracetamol thereafter), antiemetics, hydration; pain management is the critical component of UAE recovery. Fibroid expulsion: submucosal fibroids can slough into the uterine cavity and be expelled vaginally (5-10% of submucosal fibroids) — this may require hysteroscopic resection; presents as vaginal discharge, cramping, visible fibroid passage. Post-UAE amenorrhea and premature ovarian failure: occurs in 1-3% of premenopausal patients (2-4% in women over 45) due to inadvertent embolization of ovarian blood supply via anastomotic vessels; results in permanent menopause; risk discussed pre-procedure especially in women under 40. Uterine infection and sepsis: occurs in 0.5-1% — presents with fever, pelvic pain beyond 7 days, malodorous discharge; treated with broad-spectrum antibiotics; hysterectomy required in 0.1-0.3% for refractory sepsis. Endometritis: 2-5% — managed with oral antibiotics. Hysterectomy rate within 5 years: approximately 20-25% of UAE patients ultimately require hysterectomy for persistent symptoms — this is disclosed during pre-procedure counseling. Deep vein thrombosis: 0.2-0.5%; access site complications: groin hematoma (1-2%), pseudoaneurysm (0.5%). Radiation exposure: fluoroscopy of 15-30 minutes cumulative.

Post-procedure monitoring for Uterine Fibroid Embolization begins immediately after the procedure. Vital signs every 30 minutes for 2 hours, then hourly for 4–6 hours; access site assessment for haematoma, active bleeding, or pseudoaneurysm formation; serum creatinine at 24–48 hours post-contrast in patients with CKD or diabetes. Pain management with oral analgesics; adequate hydration to prevent contrast nephropathy (1,000 mL normal saline post-procedure). Short-term follow-up (1–4 weeks): clinical assessment of symptom response; duplex ultrasound or CT imaging to confirm target patency and technical success; antiplatelet therapy adherence review. Long-term surveillance (3–6–12 months): imaging surveillance for restenosis or reocclusion — timing determined by procedure type; clinical reassessment; further intervention planned early if restenosis identified before progression to total occlusion (re-intervention easier and more successful on residual stenosis than reocclusion).

Interventional radiology procedure costs for Uterine Fibroid Embolization vary by device complexity, imaging guidance, and healthcare system. India offers 75–90% cost savings vs the USA. Basic IR procedures (angiography, image-guided biopsy): $500–2,000 India vs $5,000–20,000 USA. Intermediate procedures (embolization, ablation, complex stenting): $1,500–8,000 India vs $15,000–50,000 USA. Imported devices (stents, coils, ablation probes) are 40–70% cheaper in India due to volume-based pricing. Catheterization laboratory charges: $500–2,000/session India vs $5,000–15,000/session USA. Post-procedure imaging surveillance (duplex ultrasound, CTA): $100–400 India vs $1,000–5,000 USA per study. India's leading IR centers (AIIMS, Apollo, Fortis Escorts, Narayana, Medanta, SGPGI) perform high volumes of complex procedures with outcomes matching international benchmarks, making them premier medical tourism destinations for vascular and interventional procedures. Patients should request itemized all-inclusive quotes from multiple accredited facilities to enable informed cost comparisons before committing to a treatment centre.

Open surgical repair is the primary alternative to minimally invasive Uterine Fibroid Embolization: bypass grafting, open resection, or conventional surgery offers durable outcomes for complex anatomical configurations but with substantially greater morbidity, longer hospital stays (5–10 days vs 1–2 days), and longer recovery (4–6 weeks vs 1–2 weeks). Endoscopic alternatives (ERCP, colonoscopy, bronchoscopy) are relevant for luminal interventions — choice depends on lesion location and access anatomy. Medical management alone (pharmacological risk factor control) is appropriate for asymptomatic or mildly symptomatic lesions where intervention risk exceeds benefit — validated by ISCHEMIA trial data for stable coronary disease and COURAGE trial evidence. Watchful waiting with serial surveillance imaging is reasonable for slowly progressive or anatomically benign lesions. Hybrid procedures combining open surgical exposure with endovascular techniques address complex anatomy not suitable for either approach alone.